Program
Anti-DLL3 Antibody-drug Conjugate BL-M14D1
Also written as “BL-M14D1” and “BL-M14D1 and Atezolizumab”.
In Sichuan Biokin Pharmaceutical’s pipeline, DLL3 ADC
. Its studies are mostly in Small Cell Lung Carcinoma · Carcinoma, Neuroendocrine, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biokin (Shanghai) Biopharmaceuticalits history only | 22 open or running | phase 2since Jun 12, 2026 | Jul 11, 2024 | Jun 2027phase 1 · NCT06505824 |
| Sichuan Biokin Pharmaceuticalits history only | 22 open or running | phase 3since May 21, 2026 | Jul 14, 2025 | Dec 31, 2027phase 1 · NCT07080242 |
- Named in Sichuan Biokin Pharmaceutical’s own pipeline as
BL-M14D1 (DLL3 ADC)
, phase 3, as of Nov 16, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 11, 2024First study: phase 1 study in Small Cell Lung CarcinomaNew to Biokin (Shanghai) BiopharmaceuticalBiokin (Shanghai) Biopharmaceutical · NCT06505824 · 115 planned · China
- Jul 14, 2025Sichuan Biokin Pharmaceutical’s first study: phase 1 study in Carcinoma, NeuroendocrineNew to Sichuan Biokin PharmaceuticalSichuan Biokin Pharmaceutical · NCT07080242 · 120 planned · United States, Georgia, Ukraine
- May 21, 2026Phase 3 study in Small Cell Lung CarcinomaPhase 3 reachedSichuan Biokin Pharmaceutical · NCT07625644 · 550 planned · United States, Australia, Bulgaria and more
- Jun 12, 2026Phase 2 study in Small Cell Lung CarcinomaPhase 2 reachedBiokin (Shanghai) Biopharmaceutical · NCT07654400 · 36 planned · China
Ahead
- Jun 2027Primary completion: phase 1 study in Small Cell Lung CarcinomaBiokin (Shanghai) Biopharmaceutical · NCT06505824
- Dec 2027Primary completion: phase 2 study in Small Cell Lung CarcinomaBiokin (Shanghai) Biopharmaceutical · NCT07654400
- Dec 31, 2027Primary completion: phase 1 study in Carcinoma, NeuroendocrineSichuan Biokin Pharmaceutical · NCT07080242
- Jan 2030Primary completion: phase 3 study in Small Cell Lung CarcinomaSichuan Biokin Pharmaceutical · NCT07625644
TargetBeta
“DLL3 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) ”NCIt, by rule
Other programs on DLL3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tarlatamabrule | Amgen | phase 3 | 13 |
| Alveltamigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 11 |
| obrixtamig | Boehringer Ingelheim | phase 3 | 11 |
| Zocilurtatug Pelitecanrule | Zai Lab | phase 3 | 6 |
| gocatamig | Merck | phase 3 | 4 |
| Autologous Anti-DLL3 CAR-T Cells DJI136 | Novartis | phase 2 | 2 |
| Anti-DLL3 Antibody-drug Conjugate IDE849 | ideaya-biosciences | phase 2 | 2 |
| SHR-7787 | Jiangsu HengRui Medicine | phase 2 | 1 |
| Anti-DLL3 Antibody-drug Conjugate FZ-AD005rule | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical | phase 1 | 2 |
| clesitamig | Hoffmann-La Roche | phase 1 | 2 |
| Actinium Ac 225-ABD147rule | abdera-therapeutics-inc | phase 1 | 1 |
| Indium In 111-ETN029 | Novartis | phase 1 | 1 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07654400Small Cell Lung Carcinoma · China | 2 | Recruiting | Biokin (Shanghai) Biopharmaceutical | Dec 2027 | 36 |
| NCT07625644Small Cell Lung Carcinoma · United States, Australia, Bulgaria and more | 3 | Recruiting | Sichuan Biokin Pharmaceutical | Jan 2030 | 550 |
| NCT07080242Carcinoma, Neuroendocrine · United States, Georgia, Ukraine | 1 | Recruiting | Sichuan Biokin Pharmaceutical | Dec 31, 2027 | 120 |
| NCT06505824Small Cell Lung Carcinoma · China | 1 | Recruiting | Biokin (Shanghai) Biopharmaceutical | Jun 2027 | 115 |
How it is read
Names in the registry
- “BL-M14D1”, 3 entries
- “BL-M14D1 and Atezolizumab”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 3 studies
- Carcinoma, Neuroendocrine, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.